ASH 2017 | ASH 2017: combination therapy for CLL highlights

Barbara Eichhorst

Numerous trials worldwide are now focusing on combination therapy for relapsed/refractory chronic lymphocytic leukemia (CLL). In this interview, Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, discusses the take-home messages from data for combination therapy for CLL presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video